T1	Outcomes 24 41	erectile function
T2	Outcomes 46 76	health-related quality of life
T3	Outcomes 223 263	the effectiveness and cost-effectiveness
T4	Outcomes 279 334	on erectile function and health-related quality of life
T5	Outcomes 940 1013	outcome was erectile function (International Index of Erectile Function-5
T6	Outcomes 1041 1246	included male ED-specific quality of life (MED-QoL), quality-adjusted life years (QALYs) using the generic Euroqol measure (EQ-5D), endothelial function, cardiovascular risk, cholesterol and health service
T7	Outcomes 1287 1318	difference in erectile function
T8	Outcomes 1433 1447	improvement in
T9	Outcomes 1494 1500	0.04).
T10	Outcomes 1501 1561	Both 10-year cardiovascular risk and low-density lipoprotein
T11	Outcomes 1686 1717	change in endothelial function.
T12	Outcomes 1718 1752	The frequency of sexual encounters
T13	Outcomes 1756 1799	correlated with improved erectile function.
T14	Outcomes 1800 1849	The joint distribution of costs and QALY benefits
T15	Outcomes 1884 1916	simvastatin being cost-effective
T16	Outcomes 2180 2188	analysis
T17	Outcomes 2192 2206	costs and QALY
